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ABSTRACT  
In many species, the offspring of related parents suffer reduced reproductive success, a 
phenomenon known as inbreeding depression. In humans, the importance of this effect has 
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remained unclear, partly because reproduction between close relatives is both rare and frequently 
associated with confounding social factors. Here, using genomic inbreeding coefficients (FROH) for 
>1.4 million individuals, we show that FROH is significantly associated (p < 0.0005) with apparently 
deleterious changes in 32 out of 100 traits analysed. These changes are associated with runs of 
homozygosity (ROH), but not with common variant homozygosity, suggesting that genetic variants 
causing inbreeding depression are predominantly rare. The effect on fertility is striking: FROH 
equivalent to the offspring of first cousins is associated with a 55% decrease [95% CI 44-66%] in 
the odds of having children. Finally, the effects of FROH are confirmed within full-sibling pairs, 
where the variation in FROH is independent of all environmental confounding.  
INTRODUCTION 
Given the pervasive impact of purifying selection on all populations, it is expected that genetic 
variants with large deleterious effects on evolutionary fitness will be both rare and recessive1. 
However, precisely because they are rare, most of these variants have yet to be identified and their 
recessive impact on the global burden of disease is poorly understood. This is of particular 
importance for the nearly one billion people living in populations where consanguineous marriages 
are common2, and the burden of genetic disease is thought to be disproportionately due to 
increased homozygosity of rare, recessive variants3–5. Although individual recessive variants are 
difficult to identify, the net directional effect of all recessive variants on phenotypes can be 
quantified by studying the effect of inbreeding6, which gives rise to autozygosity (homozygosity due 
to inheritance of an allele identical-by-descent). 
Levels of autozygosity are low in most of the cohorts with genome-wide data7,8 and consequently 
very large samples are required to study the phenotypic impact of inbreeding9. Here, we meta-
analyse results from 119 independent cohorts to quantify the effect of inbreeding on 45 commonly-
measured complex traits of biomedical or evolutionary importance, and supplement these with 
analysis of 55 more rarely-measured traits included in UK Biobank10.  
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Continuous segments of homozygous alleles, or runs of homozygosity (ROH), arise when identical-
by-descent haplotypes are inherited down both sides of a family. The fraction of each autosomal 
genome in ROH > 1.5 Mb (FROH) correlates well with pedigree-based estimates of inbreeding11.We 
estimate FROH using standard methods and software6,12 for a total of 1,401,776 individuals in 234 
uniform sub-cohorts. The traits measured in each cohort varied according to original study purpose, 
but together cover a comprehensive range of human phenotypes (Fig. 1, Supplementary Data Table 
7). The five most frequently contributed traits (height, weight, body mass index, systolic and diastolic 
blood pressure) were measured in >1,000,000 individuals; a further 16 traits were measured 
>500,000 times. 
We find that FROH is significantly associated with apparently deleterious changes in 32 out of 100 
traits analysed. Increased FROH is associated with reduced reproductive success (decreased number 
and likelihood of having children, older age at first sex and first birth, decreased number of sexual 
partners), as well as reduced risk-taking behaviour (alcohol intake, ever-smoked, self-reported risk 
taking) and increased disease risk (self-reported overall health, and risk factors including grip 
strength and heart rate). We show that the observed effects are predominantly caused by rare (not 
common) variants and, for a subset of traits, differ between men and women. Finally, we introduce a 
within-siblings method, which confirms that social confounding of FROH is modest for most traits. We 
therefore conclude that inbreeding depression influences a broad range of human phenotypes 
through the action of rare, recessive variants. 
RESULTS 
Cohort characteristics 
As expected, cohorts with different demographic histories varied widely in mean FROH. The within-
cohort standard deviation of FROH is strongly correlated with the mean (Pearson’s r=0.82, 
Supplementary Fig. 3), and the most homozygous cohorts provide up to 100 times greater per-
sample statistical power than cosmopolitan European-ancestry cohorts (Supplementary Data Table 
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5). To categorise cohorts, we plotted mean FROH against FIS (Fig. 2). FIS measures inbreeding as 
reflected by non-random mating in the most recent generation, and is calculated as the mean 
individual departure from Hardy-Weinberg equilibrium (FSNP, see Methods). Cohorts with high rates 
of consanguinity lie near the FROH=FIS line, since most excess SNP homozygosity is caused by ROH. In 
contrast, cohorts with small effective population sizes, such as the Amish and Hutterite isolates of 
North America, have high average FROH, often despite avoidance of mating with known relatives, 
since identical-by-descent haplotypes are carried by many couples, due to a restricted number of 
possible ancestors.  
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Traits affected by FROH 
To estimate the effect of inbreeding on each of the 100 phenotypes studied, trait values were 
regressed on FROH within each cohort, taking account of covariates including: age, sex, principal 
components of ancestry and, in family studies, a genomic relationship matrix (GRM) (Supplementary 
Data Table 3). Cross-cohort effect size estimates were then obtained by fixed-effect, inverse 
variance-weighted meta-analysis of the within-cohort estimates (Supplementary Data Table 10). 
Twenty-seven out of 79 quantitative traits and five out of 21 binary traits reach experiment-wise 
significance (0.05/100 or p<0.0005, Fig. 3a, b). Among these are replications of the previously 
reported effects on reduction in height13, forced expiratory lung volume in one second, cognition 
and education attained6. We find that the 32 phenotypes affected by inbreeding can be grouped into 
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five broader categories: reproductive success, risky behaviours, cognitive ability, body size, and 
health.  
Despite the greater individual control over reproduction in the modern era, due to contraception 
and fertility treatments, we find that increased FROH has significant negative effects on five traits 
closely related to fertility. For example, an increase of 0.0625 in FROH (equivalent to the difference 
between the offspring of first cousins and those of unrelated parents) is associated with having 0.10 
fewer children [𝛽0.0625 = -0.10±0.03 95% Confidence Interval (CI), p = 1.8x10
-10]. This effect is due to 
increased FROH being associated with reduced odds of having any children (𝑂𝑅0.0625 = 0.65±0.04, p = 
1.7x10-32) as opposed to fewer children among parents (𝛽0.0625 =0.007±0.03, p = 0.66). Since 
autozygosity also decreases the likelihood of having children in the subset of individuals who are, or 
have been, married, (𝑂𝑅0.0625 = 0.71±0.09, p = 3.8x10
-8) it appears that the cause is a reduced ability 
or desire to have children, rather than reduced opportunity. Consistent with this interpretation, we 
observe no significant effect on the likelihood of marriage (𝑂𝑅0.0625 = 0.94±0.07, p = 0.12) (Fig. 3b). 
All effect size, odds ratios and 95% confidence intervals are stated as the difference between FROH=0 
and FROH=0.0625. 
Supplementary Data TableSupplementary Data Table 
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The effects on fertility may be partly explained by the effect of FROH on a second group of traits, 
which capture risky or addictive behaviour. Increased FROH is associated with later age at first sex 
(𝛽0.0625 = 0.83±0.19 years, p = 5.8x10
-17) and fewer sexual partners (𝛽0.0625 = -1.38±0.38, p = 2.0x10
-
12) but also reduced alcohol consumption (𝛽0.0625 = -0.66±0.12 units per week, p = 1.3x10
-22), 
decreased likelihood of smoking (𝑂𝑅0.0625 = 0.79±0.05, p = 5.9x10
-13), and a lower probability of 
being a self-declared risk-taker (𝑂𝑅0.0625 = 0.84±0.06, p = 3.4x10
-5) or exceeding the speed limit on a 
motorway (p = 4.0x10-8). Conservative beliefs are likely to affect these traits, and are known to be 
confounded with FROH in some populations14, however, fitting religious participation as a covariate in 
UKB reduces, but does not eliminate the reported effects (Supplementary Figure 10b, 
Supplementary Data Table 20). Similarly, fitting educational attainment as an additional covariate 
reduces 16 of 25 significant effect estimates, but actually increases 9, including age at first sex and 
number of children (Supplementary Figure 10a, Supplementary Data Table 20). This is because 
reduced educational attainment is associated with earlier age at first sex and increased number of 
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children, which makes it an unlikely confounder for the effects of FROH, which are in the opposite 
directions. 
A third group of traits relates to cognitive ability. As previously reported, increased autozygosity is 
associated with decreased general cognitive ability, g6,15 and reduced educational attainment6. Here, 
we also observe an increase in reaction time (𝛽0.0625 = 11.6±3.9 ms, p = 6.5x10
-9), a correlate of 
general cognitive ability (Fig 3a, Supplementary Data Table 10).  
A fourth group relates to body size. We replicate previously reported decreases in height and forced 
expiratory volume6 (Supplementary Data Table 21) and we find that increased FROH is correlated with 
a reduction in weight (𝛽0.0625 = 0.86±0.12 kg, p = 3.4x10
-28) and an increase in the waist to hip ratio 
(𝛽0.0625 = 0.004±0.001, p = 1.4x10
-11). 
The remaining effects are loosely related to health and frailty; higher FROH individuals report 
significantly lower overall health and slower walking pace, have reduced grip strength (𝛽0.0625 = -
1.24±0.19 kg, p = 6.9x10-24), accelerated self-reported facial ageing, and poorer eyesight and hearing. 
Increased FROH is also associated with faster heart rate (𝛽0.0625 = 0.56±0.24 bpm, p = 5.9x10
-6), lower 
haemoglobin (𝛽0.0625 = 0.81±0.24 gL
-1, p = 1.6x10-11), lymphocyte percentage, and total cholesterol 
(𝛽0.0625 = -0.05±0.015 mmolL
-1, p = 5.2x10-10). 
Sex-specific effects of FROH 
Intriguingly, for a minority of traits (13/100), the effect of FROH differs between men and women (Fig. 
3c, Supplementary Data Table 12). For example, men who are the offspring of first cousins have 0.10 
mmolL-1 [95% CI 0.08-0.12] lower total cholesterol on average, while there is no significant effect in 
women; LDL shows a similar pattern. More generally, for these traits, the effect in men is often of 
greater magnitude than the effect in women, perhaps reflecting differing relationships between 
phenotype and fitness. 
Associations most likely caused by rare, recessive variants 
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The use of ROH to estimate inbreeding coefficients is relatively new in inbreeding research11,16–19. 
Earlier frequency-based estimators such as FSNP and FGRM20, made use of excess marker 
homozygosity21–23 and did not require physical maps. We performed both univariate and 
multivariate regressions to evaluate the effectiveness of FROH against these measures. The 
correlations between them range from 0.13 to 0.99 and are strongest in cohorts with high average 
inbreeding (Supplementary Data Table 6, Supplementary Fig. 6). Significantly, univariate regressions 
of traits on both FSNP and FGRM show attenuated effect estimates relative to FROH (Supplementary 
Data Table 13). This attenuation is greatest in low autozygosity cohorts, suggesting that FROH is a 
better estimator of excess homozygosity at the causal loci (Fig 4c).  
To explore this further, we fit bivariate models with FROH and FGRM as explanatory variables. For all 32 
traits that were significant in the univariate analysis, we find that ?̂?𝐹ROH|𝐹GRM  is of greater magnitude 
than ?̂?𝐹GRM|𝐹ROH in the conditional analysis (Fig 4b, Supplementary Data Table 22). This suggests that 
inbreeding depression is predominantly caused by rare, recessive variants made homozygous in 
ROH, and not by the chance homozygosity of variants in strong LD with common SNPs. (Figure 4d, 
Supplementary Note 5). We also find that ROH of different lengths have similar effects per unit 
length (Fig. 4a, Supplementary Fig. 11a), consistent with their having a causal effect on traits and not 
with confounding by socioeconomic or other factors, as shorter ROH arise from deep in the pedigree 
are thus less correlated with recent consanguinity. 
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Quantifying the scope of social confounding 
Previous studies have highlighted the potential for FROH to be confounded by non-genetic factors6,24. 
We therefore estimated the effect of FROH within various groups, between which confounding might 
be expected either to differ, or not be present at all. 
For example, the effect of FROH on height is consistent across seven major continental ancestry 
groups (Supplementary Fig. 1, Supplementary Data Table 18), despite differing attitudes towards 
consanguinity, and consequently different burdens and origins of ROH. Similarly, grouping cohorts 
into consanguineous, more cosmopolitan, admixed and those with homozygosity due to ancient 
founder effects also shows consistent effects (Supplementary Figure 2, Supplementary Data Table 
19). Equally, categorising samples into bins of increasing FROH shows a dose-dependent response of 
the study traits with increased FROH (Supplementary Data Table 17; Figs 5a,b show the response for 
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height and ever having children; Supplementary Figs 9a-f for all significant traits). The 
proportionality of these effects is consistent with a genetic cause, while it is difficult to envisage a 
confounder proportionally associated across the entire range of observed FROH. In particular, the 
highest FROH group (FROH > 0.18), equivalent to the offspring of first-degree relatives, are found to be, 
on average, 3.4 [95% CI 2.5-4.3] cm shorter and 3.1 [95% CI 2.5-3.7] times more likely to be childless 
than an FROH = 0 individual.  
Next, we estimated 𝛽𝐹ROHfor 7153 self-declared adopted individuals in UK Biobank, whose genotype 
is less likely to be confounded by cultural factors associated with the relatedness of their biological 
parents. For all 26 significant traits measured in this cohort, effect estimates are directionally 
consistent with the meta-analysis and 3 (height, walking pace and hearing acuity) reach replication 
significance (p < 0.004). In addition, a meta-analysis of the ratio ?̂?𝐹ROH_ADOPTEE : ?̂?𝐹ROH  across all traits 
differs significantly from zero (Fig. 5c; average = 0.78, 95% CI 0.56-1.00, p = 2 x 10-12). 
Finally, the effect of FROH was estimated in up to 118,773 individuals in sibships (full-sibling pairs, 
trios, etc.: ?̂?𝐹ROH_wSibs ). FROH differences between siblings are caused entirely by Mendelian 
segregation, and are thus independent of any reasonable model of confounding. The variation of 
FROH among siblings is a small fraction of the population-wide variation11 (Supplementary Data Table 
5), nevertheless, 23 out of 29 estimates of ?̂?𝐹ROH_wSibs are directionally consistent with ?̂?𝐹ROH , and 
two (self-reported overall health and ever having children) reach replication significance. A meta-
analysis of the ratio ?̂?𝐹ROH_wSibs : ?̂?𝐹ROH  for all traits is significantly greater than zero (Fig. 5d; average 
= 0.78, 95% CI 0.53-1.04, p = 7 x 10-10), indicating a substantial fraction of these effects is genetic in 
origin. However, for both adoptees and siblings, the point estimates are less than one, suggesting 
that non-genetic factors probably contribute a small, but significant, fraction of the observed effects. 
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DISCUSSION  
Our results reveal inbreeding depression to be broad in scope, influencing both complex traits 
related to evolutionary fitness and others where the pattern of selection is less clear. While studies 
of couples show optimal fertility for those with distant kinship25,26, fewer have examined 
reproductive success as a function of individual inbreeding. Those that did are orders of magnitude 
smaller in size than the present study, suffer the attendant drawbacks of pedigree analysis, and have 
found mixed results27–29. Our genomic approach also reveals that in addition to socio-demographic 
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factors and individual choice, recessive genetic effects have a significant influence on whether 
individuals reproduce. The discordant effects on fertility and education demonstrate that this is not 
just a result of genetic correlations between the two domains30.  
The effects we see on fertility might be partially mediated through a hitherto unknown effect of 
autozygosity on decreasing the prevalence of risk-taking behaviours. Significant effects of 
autozygosity are observed for self-reported risk taking, speeding on motorways, alcohol and smoking 
behaviour, age at first sexual intercourse and number of sexual partners. Independent evidence for a 
shared genetic architecture between risk-taking and fertility traits comes from analysis of genetic 
correlations using LD-score regression in UKB (Supplementary Table 1). The core fertility traits, ever 
had children and number of children, are strongly genetically correlated (rG = 0.93; p < 10-100). 
Genetic correlations with ever-smoking and self-reported risk-taking are lower, but also significant: 
0.23 - 0.27, p < 10-10.  Age at first sex is strongly genetically correlated both with the fertility traits, (rG 
= 0.53 - 0.57), and number of sexual partners, ever-smoking and risk-taking30, (rG = 0.42 - 0.60). 
Reproductive traits are understandable targets of natural selection, as might be walking speed, grip 
strength, overall health, and visual and auditory acuity. While we cannot completely exclude reverse 
causality, whereby a less risk-taking, more conservative, personality is associated with greater 
likelihood of consanguineous marriage, we note that the effects are consistent for ROH < 5 Mb, 
which are less confounded with mate choice, due to their more distant pedigree origins 
(Supplementary Fig 11a). This group of traits also shows similar evidence for un-confounded effects 
in the analysis of adoptees and full siblings (Figs. 5c,d; Supplementary Data Table 16) and the signals 
remained after correcting for religious activity or education.  
On the other hand, for some traits that we expected to be influenced by ROH, we observed no 
effect. For example, birth weight is considered a key component of evolutionary fitness in mammals, 
and is influenced by genomic homozygosity in deer31; however, no material effect is apparent here 
(Supplementary Data Table 10). Furthermore, in one case, ROH appear to provide a beneficial effect: 
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increasing FROH significantly decreases total and LDL-cholesterol in men, and may thus be cardio-
protective in this regard. 
Our multivariate models show that homozygosity at common SNPs outside of ROH has little 
influence on traits, and that the effect rather comes from ROH over 1.5 Mb in length. This suggests 
that genetic variants causing inbreeding depression are almost entirely rare, consistent with the 
dominance hypothesis1. The alternative hypothesis of overdominance, whereby positive selection on 
heterozygotes has brought alleles to intermediate frequencies, would predict that more common 
homozygous SNPs outside long ROH would also confer an effect. The differential provides evidence 
in humans that rare recessive mutations underlie the quantitative effects of inbreeding depression. 
Previous studies have shown that associations observed between FROH and traits do not prove a 
causal relationship14,24. Traditional Genome-wide Association Studies (GWAS) can infer causality 
because, in the absence of population structure, genetic variants (SNPs) are randomly distributed 
between, and within, different social groups. However, this assumption does not hold in studies of 
inbreeding depression, where, even within a genetically homogeneous population, social groups 
may have differing attitudes towards consanguinity, and therefore different average FROH and, 
potentially, different average trait values. We therefore present a number of analyses that discount 
social confounding as a major factor in our results. Firstly, we show that the effects are consistent 
across diverse populations, including those where ROH burden is driven by founder effects rather 
than cultural practices regarding marriage. Effects are also consistent across a 20-fold range of FROH: 
from low levels, likely unknown to the subject, to extremely high levels only seen in the offspring of 
first-degree relatives. Secondly, we show that the effects of ROH are consistent in direction and 
magnitude among adopted individuals, and also for short ROH which are not informative about 
parental relatedness. Finally, we introduce a within-siblings method, independent of all 
confounders, that confirms a genetic explanation for most of the observed effects. Variation in FROH 
between siblings is caused entirely by random Mendelian segregation; we show that higher FROH 
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siblings experience: poorer overall health and lower reproductive success, as well as other changes 
consistent with population-wide estimates. Nevertheless, average effect sizes from both adoptees 
and siblings are 20% smaller than population-wide estimates, confirming the importance of 
accounting for social confounding in future studies of human inbreeding depression. 
Our results reveal five large groups of phenotypes sensitive to inbreeding depression, including some 
known to be closely linked to evolutionary fitness, but also others where the connection is, with 
current knowledge, more surprising. The effects are mediated by ROH rather than homozygosity of 
common SNPs, causally implicating rare recessive variants rather than overdominance as the most 
important underlying mechanism. Identification of these recessive variants will be challenging, but 
analysis of regional ROH and in particular using whole genome sequences in large cohorts with 
sufficient variance in autozygosity will be the first step. Founder populations or those which prefer 
consanguineous marriage will provide the most power to understand this fundamental 
phenomenon.  
Supplementary Data Table 
METHODS 
Overview 
Our initial aim was to estimate the effect of FROH on 45 quantitative traits and to assess whether any 
of these effects differed significantly from zero. Previous work7,11 has shown that inbreeding 
coefficients are low in most human populations, and that very large samples are required to reliably 
estimate the genetic effects of inbreeding13. To maximize sample size, a collaborative consortium 
(ROHgen6) was established, and research groups administering cohorts with SNP chip genotyping 
were invited to participate. To ensure that all participants performed uniform and repeatable 
analyses, a semi-automated software pipeline was developed and executed locally by each research 
group. This software pipeline required cohorts to provide only quality-controlled genotypes (in plink 
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binary format) and standardised phenotypes (in plain-text) and used standard software (R, 
PLINK12,32, KING33) to perform the analyses described below. Results from each cohort were returned 
to the central ROHgen analysts for meta-analysis.  
During the initial meta-analysis, genotypes were released for >500,000 samples from the richly 
phenotyped UK Biobank (UKB)10. It was therefore decided to add a further 34 quantitative 
phenotypes and 21 binary traits to the ROHgen analysis. Many of these additional traits were unique 
to UKB, although 7 were also available in a subset of ROHgen cohorts willing to run additional 
analyses. In total, the effect of FROH was tested on 100 traits and therefore experiment-wise 
significance was defined as 5 x 10-4 (=0.05/100). 
Cohort recruitment 
In total, 119 independent, genetic epidemiological study cohorts were contributed to ROHgen. Of 
these, 118 were studies of adults and contributed multiple phenotypes, while 1 was a study of 
children and contributed only birth weight. To minimize any potential confounding or bias caused by 
within-study heterogeneity, studies were split into single-ethnicity sub-cohorts wherever applicable. 
Each sub-cohort was required to use only one genotyping array and be of uniform ancestry and case-
status. For example, if a study contained multiple distinct ethnicities, sub-cohorts of each ancestry 
were created and analysed separately. At minimum, ancestry was defined on a sub-continental scale 
(i.e. European, African, East Asian, South Asian, West Asian, Japanese and Hispanic were always 
analysed separately) but more precise separation was used when deemed necessary, for example in 
cohorts with large representation of Ashkenazi Jews. In case-control studies of disease, separate 
sub-cohorts were created for cases and controls and phenotypes associated with disease status 
were not analysed in the case cohort: for example, fasting plasma glucose was not analysed in Type 
2 diabetes case cohorts. Occasionally, cohorts had been genotyped on different SNP genotyping 
microarrays and these were also separated into sub-cohorts. There was one exception (deCODE) to 
the single microarray rule, where the intersection between all arrays used exceeded 150,000 SNPs. 
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In this cohort the genotype data from all arrays was merged since the correspondence between FROH 
for the individual arrays and FROH the intersection dataset was found to be very strong (𝛽merged,hap 
=0.98, r2=0.98, 𝛽merged,omni=0.97, r
2=0.97). Dividing studies using these criteria yielded 234 sub-
cohorts. Details of phenotypes contributed by each cohort are available in Supplementary Data 
Table 4.  
Ethical approval 
Data from 119 independent genetic epidemiology studies were included. All subjects gave written 
informed consent for broad-ranging health and genetic research and all studies were approved by 
the relevant research ethics committees or boards. PubMed references are given for each study in 
Supplementary Data Table 2. 
Genotyping 
All samples were genotyped on high-density (minimum 250,000 markers), genome-wide SNP 
microarrays supplied by Illumina or Affymetrix. Genotyping arrays with highly variable genomic 
coverage (such as Exome chip, Metabochip or Immunochip) were judged unsuitable for the ROH 
calling algorithm and were not permitted. Imputed genotypes were also not permitted; only called 
genotypes in PLINK binary format were accepted. Each study applied their own GWAS quality 
controls before additional checks were made in the common analysis pipeline: SNPs with > 3% 
missingness or MAF < 5% were removed, as were individuals with > 3% missing data. Only autosomal 
genotypes were used for the analyses reported here. Additional, cohort-specific, genotyping 
information is available in Supplementary Data Table 2. 
Phenotyping 
In total, results are reported for 79 quantitative traits and 21 binary traits. These traits were chosen 
to represent different domains of health and reproductive success, with consideration given to 
presumed data availability. Many of these traits have been the subject of existing genome-wide 
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association meta-analyses (GWAMA), and phenotype modelling, such as inclusion of relevant 
covariates, was copied from the relevant consortia (GIANT for anthropometry, EGG for birth weight, 
ICBP for blood pressures, MAGIC for glycaemic traits, CHARGE-Cognitive, -Inflammation & -
Haemostasis working groups for cognitive function, CRP, fibrinogen, CHARGE-CKDgen for eGFR, 
CHARGE-ReproGen for ages at menarche and menopause, Blood Cell & HaemGen for haematology, 
GUGC for urate, RRgen, PRIMA, QRS & QT-IGC for electrocardiography, GLGC for classical lipids, 
CREAM for spherical equivalent refraction, Spirometa for lung function traits, and SSGAC for 
educational attainment and number of children ever born).  Further information about individual 
phenotype modelling is available in Supplementary Note 1 and Supplementary Data Table 8. 
ROH calling 
ROH of > 1.5 Mb in length were identified using published methods6,11. In summary, SNPs with minor 
allele frequencies below 5% were removed, before continuous runs of homozygous SNPs (ROH) 
were identified using PLINK with the following parameters: homozyg-window-snp 50; homozyg-snp 
50; homozyg-kb 1500; homozyg-gap 1000; homozyg-density 50; homozyg-window-missing 5; 
homozyg-window-het 1.  No linkage disequilibrium pruning was performed. These parameters have 
been previously shown to call ROH that correspond to autozygous segments in which all SNPs 
(including those not present on the chip) are homozygous-by-descent, not chance arrangements of 
independent homozygous SNPs, and inbreeding coefficient estimates calculated by this method 
(FROH) correlate well with pedigree-based estimates (FPED)11. Moreover, they have also been shown to 
be robust to array choice6. 
Calculating estimators of F 
For each sample, two estimates of the inbreeding coefficient (F) were calculated, FROH and FSNP. We 
also calculated three additional measures of homozygosity: FROH<5Mb, FROH>5Mb and FSNP_outsideROH. 
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FROH is the fraction of each genome in ROH > 1.5 Mb. For example, in a sample for which PLINK had 
identified n ROH of length li (in Mb), i ϵ {1..n}, then FROH was then calculated as 
𝐹ROH =  
∑ 𝑙𝑖
𝑛
𝑖=1
3𝐺𝑏
(1) 
Where FROH<5Mb and FROH>5Mb are the genomic fractions in ROH of length >5 Mb, and in ROH of length 
< 5Mb (but > 1.5 Mb), respectively, and the length of the autosomal genome is estimated at 3 
gigabases (Gb). It follows from this definition that: 
𝐹ROH =  𝐹ROH>5Mb +  𝐹ROH<5Mb (2) 
Single-point inbreeding coefficients can also be estimated from individual SNP homozygosity without 
any reference to a genetic map. For comparison with FROH, a method of moments estimate of 
inbreeding coefficient was calculated34, referred to here as FSNP, and implemented in PLINK by the 
command --het. 
𝐹SNP =
𝑂(𝐻𝑂𝑀) − 𝐸(𝐻𝑂𝑀)
𝑁 − 𝐸(𝐻𝑂𝑀)
(3) 
Where O(HOM) is the observed number of homozygous SNPs, E(HOM) is the expected number of 
homozygous SNPs, i.e. ∑ (1 − 2𝑝𝑖𝑞𝑖
𝑁
𝑖=1 ), and N is the total number of non-missing genotyped SNPs.  
FROH and FSNP are strongly correlated, especially in cohorts with significant inbreeding, since both are 
estimates of F. To clarify the conditional effects of FROH and FSNP, an additional measure of 
homozygosity, 𝐹SNPoutsideROH , was calculated to describe the SNP homozygosity observed outside 
ROH.  
𝐹SNPoutsideROH =
𝑂′(𝐻𝑂𝑀) − 𝐸′(𝐻𝑂𝑀)
𝑁′ − 𝐸′(𝐻𝑂𝑀)
(4) 
where 
𝑂′(𝐻𝑂𝑀) = 𝑂(𝐻𝑂𝑀) − 𝑁SNP_ROH (5) 
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𝐸′(𝐻𝑂𝑀) =  (
𝑁 − 𝑁ROH
𝑁
) ∗ 𝐸(𝐻𝑂𝑀) (6) 
𝑁′ = 𝑁 −  𝑁ROH (7) 
And 𝑁SNP_ROH is the number of homozygous SNPs found in ROH. Note that: 
𝐹SNPoutsideROH ≈  𝐹SNP −  𝐹ROH (8) 
 
A further single point estimator of the inbreeding coefficient, described by Yang et al.20 as ?̂?𝐼𝐼𝐼, is 
implemented in PLINK by the parameter –ibc (Fhat3) and was also calculated for all samples. 
                                               𝐹GRM = ?̂?
𝐼𝐼𝐼 =
1
𝑁
∑
(𝑥𝑖
2 − (1 + 2𝑝𝑖)𝑥𝑖 + 2𝑝𝑖
2)
2𝑝𝑖(1 − 𝑝𝑖)
𝑁
𝑖=1
                                          (9) 
Where 𝑁 is the number of SNPs, 𝑝𝑖  is the reference allele frequency of the i
th SNP in the sample 
population and 𝑥𝑖 is the number of copies of the reference allele. 
 
Effect size estimates for quantitative traits 
In each cohort of n samples, for each of the quantitative traits measured in that cohort, trait values 
were modelled by 
𝐲 =  𝛽𝐹ROH ∗ 𝐅𝐑𝐎𝐇 + 𝐗𝐛 +  𝛆 (10) 
where y is a vector (n x 1) of measured trait values, 𝛽𝐹ROH  is the unknown scalar effect of FROH on the 
trait, FROH is a known vector (n x 1) of individual FROH, b is a vector (m x 1) of unknown fixed covariate 
effects (including a mean, μ), X in a known design matrix (n x m) for the fixed effects, and ε is an 
unknown vector (n x 1) of residuals. 
The m fixed covariates included in each model were chosen with reference to the leading GWAMA 
consortium for that trait and are detailed in Supplementary Data Table 8. For all traits, these 
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covariates included: age (and/or year of birth), sex, and at least the first 10 principal components of 
the genomic relatedness matrix (GRM). Where necessary, additional adjustments were made for 
study site, medications, and other relevant covariates. (Supplementary Data Table 3) 
For reasons of computational efficiency, it was decided to solve equation (10) in two steps. In the 
first step, the trait (y) was regressed on all fixed covariates to obtain the maximum likelihood 
solution of the model: 
𝐲 = 𝐗𝐛 +  𝛆′ (11) 
All subsequent analyses were performed using the vector of trait residuals ε’, which may be 
considered as the trait values corrected for all known covariates. 
In cohorts with a high degree of relatedness, mixed-modelling was used to correct for family 
structure, although, because ROH are not narrow-sense heritable, this was considered less essential 
than in Genome-Wide Association Studies. Equation (11) becomes 
𝐲 = 𝐗𝐛 + 𝐮 +  𝛆′ (12) 
Where u is an unknown vector (n x 1) of polygenic effects with multivariate normal distribution of 
mean 0 and covariance matrix σg2A, where A is the genomic relationship matrix (GRM). In these 
related cohorts, a GRM was calculated using PLINK v1.9 and Grammar+ residuals of equation (12) 
were estimated using GenABEL35. These Grammar+ residuals (ε’) were used in subsequent analyses. 
To estimate 𝛽𝐹ROHfor each trait, trait residuals were regressed on FROH to obtain the maximum 
likelihood (ML) solution of the model 
𝛆′ =  𝜇 +  𝛽𝐹ROH ∗ 𝐅𝐑𝐎𝐇 +  𝛆 (13) 
The sex-specific estimates of 𝛽𝐹ROH  (Supplementary Data Table 12) were obtained from equation 
(13) applied to the relevant sex. 
For all traits, a corresponding estimates of 𝛽𝐹SNP  and 𝛽𝐹GRM  were obtained from the models 
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𝛆′ =  𝜇 +  𝛽𝐹SNP ∗ 𝐅𝐒𝐍𝐏 + 𝛆 (13) 
𝛆′ =  𝜇 +  𝛽𝐹GRM ∗ 𝐅𝐆𝐑𝐌 + 𝛆 (14) 
and the effects of different ROH lengths, and of SNP homozygosity (Fig. 4b), were obtained from the 
model  
𝛆′ =  𝜇 + (𝛽1 ∗ 𝐅𝐒𝐍𝐏𝐨𝐮𝐭𝐬𝐢𝐝𝐞𝐑𝐎𝐇) + (𝛽2 ∗ 𝐅𝐑𝐎𝐇<𝟓𝐌𝐛) + (𝛽3 ∗ 𝐅𝐑𝐎𝐇>𝟓𝐌𝐛) +  𝛆 (15) 
 
Effect size estimates for binary traits 
Binary traits were analysed by two methods. The primary estimates of 𝛽𝐹ROH  (Fig. 3b and 
Supplementary Data Table 10), were obtained from full logistic models: 
𝑔(𝐸[𝐲]) = 𝐗𝐛 (16) 
Where g() is the link function (logit), and where FROH and all applicable covariates (Supplementary 
Data Tables 3, 8) were fitted simultaneously. Mixed modelling for family structure was not 
attempted in the logistic models since an accepted method was not apparent. 
For all subsequent results, y was scaled by 1/𝜎𝑦
2 and analysed by linear models, as for quantitative 
traits, including mixed-modelling where appropriate for family studies. This method of estimating 
binary traits with simple linear models gives asymptotically unbiased estimates of 𝛽𝐹ROH  and 
se(𝛽𝐹ROH) on the ln(Odds-Ratio) scale
36. For all significant binary traits, a comparison of ?̂?𝐹ROH  from 
the full model with ?̂?𝐹ROHfrom the linear model approximation is presented in Supplementary Fig. 8. 
To give ?̂?𝐹ROHa more tangible interpretation, effect estimates are frequently quoted in the text as 
β0.0625, i.e. the estimated effect in the offspring of first cousins, where 6.25% of the genome is 
expected to be autozygous. 
Religiosity and Educational Attainment as additional covariates 
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To assess the importance of potential social confounders, proxy measures of socio-economic status 
and religiosity were separately included in equation (13) as additional covariates. The modified 
effect estimates (𝛽′̂𝐹ROH
) were tested for significance (Supplementary Data Table 20) and compared 
to the uncorrected estimates (𝛽𝐹ROH) (Supplementary Fig. 10a,b). 
Since Educational Attainment (EA) was measured in many cohorts, this was chosen as the most 
suitable proxy for socio-economic status. However, since FROH is known to affect EA directly6 any 
change in 𝛽𝐹ROHwhen conditioning on EA cannot be assumed to be entirely due to environmental 
confounding. 
The analysis of religiosity was only carried out in UKB, where a rough proxy was available. Although 
no direct questions about religious beliefs were included, participants were asked about their leisure 
activities. In response to the question Which of the following do you attend once a week or more 
often? (You can select more than one), 15.6% of UKB participants selected Religious Group from one 
of the seven options offered. In the models described, religiosity was coded as 1 for those who 
selected Religious Group and 0 for those who did not. Although this is likely to be an imperfect 
measure of actual religious belief it is currently the best available in a large dataset. 
Assortative mating 
Humans are known to mate assortatively for a number of traits including height and cognition37, and 
so we sought to investigate if this could influence our results, for example by the trait extremes 
being more genetically similar and thus the offspring more homozygous. We see no evidence for an 
effect of assortative mating on autozygosity, however. Firstly, a polygenic risk score for height (see 
Supplementary Note 1), which explains 18.7% of the phenotypic variance in height, was not 
associated with FROH (p = 0.77; Supplementary Fig. 5).  Secondly, linear relationships between traits 
and autozygosity extend out to very high FROH individuals (Supplementary Figs. 9a-f ). Samples in the 
highest FROH group are offspring of genetically similar parents, very likely 1st or 2nd degree relatives 
and, for example, the height of these samples is on average 3.4 cm [95% CI 2.5-4.3] shorter than the 
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population mean. Assortative mating would suggest this height deficit has been inherited from 
genetically shorter parents, but this would require an implausibly strong relationship between short 
stature and a propensity to marry a very close relative. Thirdly, the sex-specific effects we observe 
could only be explained by assortative mating if the additive heritability of these traits also differed 
by gender. 
Average trait values in groups of similar FROH 
In each cohort individuals were allocated to one of ten groups of similar FROH. The bounds of these 
groups were the same for all cohorts, specifically {0, 0.002, 0.0041, 0.0067, 0.0108, 0.0186, 0.0333, 
0.06, 0.10, 0.18 and 1.0}. Within each group the mean trait residual (ε’) and mean FROH were 
calculated, along with their associated standard errors.  Within each cohort the expectation of ε’ is 
zero at the mean FROH, however as mean FROH varies between cohorts (Fig. 2, Supplementary Data 
Table 5) it was necessary to express ε’ relative to a common FROH before meta-analysis. Hence, for 
this analysis only, the trait residuals (ε’) were expressed relative to the FROH=0 intercept, i.e. by 
subtracting μ from equation (13). 
 
Effect of FROH within adoptees  
We compared 𝛽𝐹ROH_ADOPTEE  to cross-cohort 𝛽𝐹ROH , not that from UKB alone, as we consider the 
latter to be a noisy estimate of the former; estimates in UKB are consistent with those from meta-
analysis. 
Effect of FROH within full-sibling families  
In a subset of cohorts, with substantial numbers of related individuals, further analyses were 
performed to investigate the effect of FROH within full-sibling families. In each of these cohorts, all 2nd 
degree, or closer, relatives were identified using KING (parameters: --related --degree 2). Full-siblings 
were then selected as relative pairs with genomic kinship > 0.175 and IBS0 > 0.001. This definition 
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includes monozygotic twins, who were intentionally considered as part of full-sibling families. 
Although monozygotic twins are expected to have identical FROH, they may not have identical trait 
values, and including additional trait measurements decreases the sampling error of the within-
family variance estimate, hence increasing statistical power. Dizygotic twins were also included. 
For each individual (j) with identified siblings, the values of FROH and trait residual (ε’) were calculated 
relative to their family mean (and called FjROH_wSibs and εjwSibs, respectively), i.e. for individual j with n 
full-siblings Sk where k ϵ {1..n} 
𝐹𝑗
ROHwSibs = 𝐹𝑗
ROH −  
1
(𝑛 + 1)
∑ 𝐹𝑖
ROH
𝑖𝜖{𝑗,𝑆𝑘}
(17) 
 
𝜀𝑗
wSibs = 𝜀𝑗
′ − 
1
(𝑛 + 1)
∑ 𝜀′𝑖
𝑖𝜖{𝑗,𝑆𝑘}
(18) 
 
The effect of FROH within-full-siblings (𝛽𝐹ROH_wSibs ) was estimated by linear regression of ε
wSibs on 
FROH_wSibs. 
Importantly, the variation of FROH within full-siblings is entirely caused by differences in Mendelian 
segregation, and is therefore completely independent of all possible confounders. Hence, the effect 
estimates obtained by this method are estimates of the genetic effects of FROH, unbiased by any 
possible confounder. 
Importantly, the variation of FROH within full-siblings is entirely caused by differences in Mendelian 
segregation, and is therefore completely independent of all possible confounders. Hence, the effect 
estimates obtained by this method are estimates of the genetic effects of FROH, unbiased by any 
possible confounder. Since confounding by social factors is a major concern in this field, methods 
that can definitively exclude this possibility are of critical importance. 
 38 
 
Between cohort meta-analysis 
As is typical in genome-wide association meta-analyses (GWAMA), genetic effects were estimated 
within single-ethnicity sub-cohorts, and meta-analysis of the within-cohort effect sizes was used to 
combine results38. This established method eliminates any potential confounding caused by 
between-cohort associations between FROH and traits.  
Each cohort returned estimates and standard errors of: 𝛽𝐹ROH , 𝛽𝐹SNP , 𝛽𝐹ROH>5Mb, 𝛽𝐹ROH<5Mb, 
𝛽𝐹SNP_outsideROH , 𝛽𝐹ROH_wSibs , as well as trait means (𝜀
′̅) and standard errors within each of 10 FROH 
bins.  The between-cohort mean of each of these 16 estimates was then determined by fixed-effect, 
inverse-variance meta-analysis using the R package metafor39. Results shown in Figs. 3, 4 and 5 are 
meta-analysed averages of the within-cohort effects. 
The meta-analysis was also run for various subsets of cohorts, stratified by ancestry as defined in 
Supplementary Data Table 18. Meta-analysis estimates from these groupings are shown in 
Supplementary Fig. 1. 
Median and 95% confidence interval of a ratio 
In the analyses of adoptees (Fig. 5c), siblings (Fig. 5d) and potential confounders (Supplementary 
Figs. 10a,b) we wished to compare the effect estimates (𝛽𝐹ROH) from two different methods across a 
wide range of traits. The units of 𝛽𝐹ROHdiffer by trait so, to allow comparison across all traits, the 
unitless ratio of effect size estimates was calculated (for example 𝛽𝐹ROH_wSibs : 𝛽𝐹ROH). Figs. 5c, d and 
Supplementary Figs. 10a,b show the medians and 95% confidence intervals of these ratios. These 
were determined empirically by bootstrap since, although formulae exist for the mean and standard 
error of a ratio40, the assumption of normality is violated when 𝛽𝐹ROH  / se(𝛽𝐹ROH) is not large. 
Genetic correlations in UK Biobank 
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Genetic correlations were calculated using LD-Score Regression41, implemented in LDSC v1.0.0 
(https://github.com/bulik/ldsc). Summary statistics were parsed using default parameters in the 
LDSC ‘munge_sumstats.py’ script, extracting only variants present in the HapMap 3 reference panel. 
Accuracy of FROH measures of inbreeding effects 
A recent paper suggested that ROH may overestimate inbreeding effects by as much as 162%42; 
however, this could only be the case if FROH underestimates excess homozygosity at the causal loci by 
at least 162%. We do not believe this to be the case since the maximum FROH measured in many 
cohorts is around 0.25 (the expectation in the offspring off first-degree relatives), and the effect size 
estimates from these samples are consistent with the overall estimates (Fig. 5c, d and 
Supplementary Fig. 9a-f). We note that Yengo et al. applied the ROH calling parameters used here to 
imputed data. These parameters have been validated for called genotype data6 but not, to our 
knowledge, for the higher SNP density and error rate of imputed data (See also Supplementary Note 
4). The simple method for detecting ROH used here was well suited to our study, since it could be 
easily implemented on over one million samples, and most of the variation in FROH is caused by 
easily-identified long ROH.43–45 
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FIGURE LEGENDS 
 
Figure 1. Census of complex traits. Sample sizes are given for analyses of 57 representative 
phenotypes, arranged into 16 groups covering major organ systems and disease risk factors. HDL, 
high density lipoprotein; LDL, low density lipoprotein, hs-CRP, high sensitivity C-reactive protein; 
TNF-alpha, tumour necrosis factor alpha; FEV1, forced expiratory volume in one second; FVC, 
forced vital capacity; eGFR, estimated glomerular filtration rate.  
Figure 2. Mean FROH and FIS for 234 ROHgen sub-cohorts. Each cohort is represented by a circle 
whose area is proportional to the approximate statistical power (𝑁𝜎𝐹ROH
2 ) contributed to 
estimates of 𝛽𝐹ROH . Mean FROH can be considered as an estimate of total inbreeding relative to an 
unknown base generation, approximately tens of generations past. FIS measures inbreeding in the 
current generation, with FIS = 0 indicating random mating, FIS > 0 indicating consanguinity, and FIS 
< 0 inbreeding avoidance46.  In cohorts along the y-axis, such as the Polynesians and the 
Anabaptist isolates, autozygosity is primarily caused by small effective population size rather than 
preferential consanguineous unions. In contrast, in cohorts along the dotted unity line, all excess 
SNP homozygosity is accounted for by ROH, as expected of consanguinity within a large effective 
population. A small number of cohorts along the x-axis, such as Hispanic and mixed-race groups, 
show excess SNP homozygosity without elevated mean FROH, indicating population genetic 
structuring, caused for instance by admixture and known as the Wahlund effect. A few notable 
cohorts are labelled. BBJ, Biobank Japan; BiB, Born in Bradford; UKB, UK Biobank; MESA, 
Multiethnic Study of Atherosclerosis; TCGS, Tehran Cardiometabolic Genetic Study.  
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Figure 3. Scope of inbreeding depression (a) Effect of FROH on 25 quantitative traits. To facilitate 
comparison between traits, effect estimates are presented in units of within-sex standard 
deviations. Traits shown here reached Bonferroni-corrected significance of p = 0.0005 (=0.05/100 
traits). Sample sizes, within-sex standard deviations, and effect estimates in measurement units 
are shown in Supplementary Data Table 9. FEV1, forced expiratory volume in one second. Traits 
are grouped by type. (b) Effect of FROH on 8 binary traits with associated p-values. Effect 
estimates are reported as ln(Odds-Ratio) for the offspring of first cousins, for which E(FROH) = 
0.0625. Self-declared infertility is shown for information, although this trait does not reach 
Bonferroni corrected significant (𝑂𝑅0.0625 = 2.6±1.1, p = 0.0006). Numbers of cases and controls 
and effect estimates for all binary traits are shown in Supplementary Data Table 10. (c) Sex-
specificity of ROH effects. The effect of FROH in men versus that in women is shown for 13 traits 
for which there was evidence of significant differences in the effects between sexes. For 11 of 
these 13 traits the magnitude of effect is greater in men than in women. Traits such as liver 
enzymes levels (alanine transaminase, gamma-glutamyl transferase) show sex-specific effects of 
opposite sign (positive in women, negative in men), which cancel out in the overall analysis. BMI, 
body mass index; LDL low density lipoprotein. All errors bars represent 95% confidence intervals. 
Figure 4. Inbreeding depression caused by ROH a) Effect of different ROH lengths on height, 
compared with the effect of SNP homozygosity outside of ROH. The effects of shorter (<5 Mb) 
and longer (>5 Mb) ROH per unit length are similar and strongly negative, whereas the effect of 
homozygosity outside ROH is much weaker. The pattern is similar for other traits (Supplementary 
Fig. 11a; Supplementary Data Table 14). (b) 𝑭𝐑𝐎𝐇 is more strongly associated than 𝑭𝐆𝐑𝐌 in a 
bivariate model of height. Meta-analysed effect estimates, and 95% confidence intervals, are 
shown for a bivariate model of height (𝐻𝑒𝑖𝑔ℎ𝑡 ~ 𝐹ROH + 𝐹GRM). The reduction in height is more 
strongly associated with 𝐹ROH than 𝐹GRM, as predicted if the causal variants are in weak LD with 
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the common SNPs used to calculate 𝐹GRM (Supplementary Note 5). The pattern is similar for 
other traits (Supplementary Fig. 15a, b; Supplementary Data Table 22). (c) FROH is a lower 
variance estimator of the inbreeding coefficient than FGRM. The ratio of 𝛽𝐹GRM : 𝛽𝐹ROH  is plotted 
against 
𝑣𝑎𝑟(𝐹ROH)
𝑣𝑎𝑟(𝐹GRM)
 for all traits in all cohorts. When the variation of 𝐹GRM which is independent of 
𝐹ROH has no effect on traits, ?̂?𝐹GRM  is downwardly biased by a factor of 
𝑣𝑎𝑟(𝐹ROH)
𝑣𝑎𝑟(𝐹GRM)
 (Supplementary 
Note 4). A linear maximum likelihood fit, shown in red, has a gradient consistent with unity [1.01; 
95% CI 0.84 – 1.18], as expected when the difference between 𝐹GRM and 𝐹ROH is not informative 
about the excess homozygosity at causal variants. (Supplementary Note 5). (d) FROH is a better 
predictor of rare variant homozygosity than FGRM. The excess homozygosities of SNPs, extracted 
from UK Biobank imputed genotypes, were calculated at seven discrete minor allele frequencies 
(𝐹MAF), and regressed on two estimators of inbreeding in a bivariate statistical model (See 
Supplementary Note 5). The homozygosity of common SNPs is better predicted by 𝐹GRM, but rare 
variant homozygosity is better predicted by 𝐹ROH. The results from real data (Fig. 4b, 
Supplementary  Figs 15a,b and Supplementary Data Table 22) are consistent with those simulated 
here, if the causal variants are predominantly rare. All errors bars represent 95% confidence 
intervals. 
 
 
Figure 5. Evidence ROH effects are un-confounded, (a) Linear decrease in height with increasing 
FROH. Average heights (in metres) is plotted in bins of increasing FROH. The limits of each bin are 
shown by red dotted lines, and correspond to the offspring of increasing degree unions left-to-
right. The overall estimate of 𝛽𝐹ROH  is shown as a solid black line. Subjects with kinship equal to 
offspring of full-sibling or parent-child unions are significantly shorter than those of avuncular or 
half-sibling unions who in turn are significantly shorter than those of first-cousin unions. (b) 
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Linear decrease in odds of ever having children with increasing FROH. Linear model 
approximations of ln(Odds-Ratio) for ever having children (1 = parous, 0 = childless) are plotted in 
bins of increasing FROH. A strong relationship is evident, extending beyond the offspring of first 
cousins. (c) ROH effects are consistent in adoptees. The ratios of effect estimates, 𝛽𝐹ROH , 
between adoptees and all individuals are presented by trait. All traits are directionally consistent 
and overall show a strongly significant difference from zero (average = 0.78, 95% CI 0.56-1.00, p = 
2 x 10-12). FEV1, forced expiratory volume in one second. (d) ROH effects are consistent in full 
siblings. The ratios of effect estimates within full siblings to effects in all individuals 
(𝛽𝐹ROH_wSibs : 𝛽𝐹ROH) are presented by trait. 23 of 29 estimates are directionally consistent and 
overall show a significant difference from zero (average = 0.78, 95% CI 0.53-1.04, p = 7 x 10-10). 
BMI, body mass index. All errors bars represent 95% confidence intervals. 
 
 
 
 
